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1. Introduction 
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults 
(American Cancer Society, 2010) however overall survival rate remain poor despite 
advancement in treatment modality.  
Since the last 50 years, systemic chemotherapy has greatly improved outcome in many types 
of cancers. The use of continuous infusion Arabinosylcytosine (Ara-C) combined with 
another agent, usually an anthracycline or anthracenedione, the “3+7” regimen, has been the 
backbone of induction therapy for AML cases (Yates et al., 1973). An attempt to add other 
drugs (Preisler et al., 1987) and intensification of the Ara-C dose (Schiller et al., 1992; Weick 
et al., 1996) to this approach has achieved some degree of success. Currently more work is 
attempted at improving patient outcome by intensifying the doses of anthracyclines 
(Lowenberg et al., 2010a) or by adding targeted therapies like gemtuzumabozogamicin 
(Lowenberg et al., 2010b; Nabhan et al., 2005). 
For consolidation therapy, the use of Ara-C with or without other agents has been 
employed to maintain remission and cure. Allogeneic hematopoietic cell transplantation 
(HCT) based on initial cytogenetic (Cornelissen et al., 2007; Koreth et al., 2009) and 
molecular studies (Castaigne et al., 2004) have been proposed as an alternative 
consolidation therapies. 
Induction therapy aims to produce complete remission (CR) defined as a marrow with 
less than 5% blast, a neutrophil count greater than 1000/mm3 and a platelet count greater 
than 100,000/mm3 (Cheson et al., 2003). Majority of younger patients (65-75%) will 
achieve CR after receiving induction treatment while CR in elderly group is much lower 
(40-50%).  
Patients who do not respond to induction treatment display chemotherapy resistance (Estey 
et al., 1996). In trials done by the Southwest Oncology Group (SWOG), resistant disease was 
found in about 33% (patients younger than 56 ) out of 404 patients’ enrolled into the studies, 
62% for patients in between 56-65 year old, 61% for patients between 66-75 years old and 
57% for age more than 75 year old (Frederick et al., 2006).  
Resistance is also common at relapse (Estey et al., 1996). Relapse itself could be due to 
resistance to treatment in a subgroup of leukaemic cells which survived induction therapy 
despite CR. Patients usually relapse within two to three years after achieving CR. 
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2. Multi-drug resistance protein as a mechanism of drug resistance 
Development of drug resistance is a major problem in AML therapy. It will eventually occur 
in most haematological malignancies treated with chemotherapy. Classically, drug 
resistance is divided into extrinsic and intrinsic (Jean-Pierre et al., 2003). Extrinsic resistance 
(host factors) refers to the inability of the drug to reach the tumour cell. It occurs when the 
bioavailability of the oral form varies from patient to patient like poor absorption resulting 
in low serum levels.  
Intrinsic (cellular) resistance is due to properties of the tumour cell. It can be classified as 
simple resistance, when cells are resistant to only one particular drug, or as multidrug 
resistance (MDR) when cross resistance is observed among chemotherapeutic drugs with 
different biochemical targets. Multidrug resistance is more common than simple resistance 
and it can be due to several mechanisms. The most common pharmacological mechanism 
involved is due to an active efflux of drugs from the tumour cells or enhanced drug 
metabolism which prevented the drug from reaching its target in the nucleus.  
The most important protein described in MDR cells is P-glycoprotein (P-gp), a 
transmembrane energy-dependent drug efflux pump, which is most efficient at transporting 
naturally occurring substances. It is encoded by the MDR1/ABCB1 gene and belongs to a 
superfamily of ABC (ATP binding cassette) transporters. P-gp expression in AML at initial 
presentation has been reported to be 20% to 40% (Motoji T et al., 2000). Increase in P-gp 
expression in leukaemic cells causes reduced intracellular concentration of cytotoxic drugs. 
There are many drugs used in AML that are transported by P-gp including anthracyclines 
and anthracenediones like daunorubicin and mitoxantrone, the vinca alkaloids (vincristine 
and vinblastine) and the epipodophyllotoxins (etoposide and teniposide). 
Other ABC transport proteins that have been implicated in MDR include the multi-drug 
resistance associated proteins (MRP1/ABCC1) and the breast cancer resistance protein 
(BCRP/ABCG2). All these proteins are not unique to drug resistance cells but expressed in 
tissue with excretory and secretory functions. However, many studies have found that 
overexpression of these proteins correlate with poor treatment response (Damiani et al., 
2010; Bendarra et al., 2005). 
A non-ABC protein, found widely expressed in P-gp negative multidrug resistant cancer cell 
termed initially as lung resistance related protein (LRP) and now known as major vault 
protein (MVP) also has been implicated in drug resistance mechanism (Izquierdo et al., 1996; 
Huh et al., 2006). This protein is involved in bidirectional transportation of a variety of 
substrates between nucleus and cytoplasm. It is present in many cells and seems to be 
upregulated in cancer cells and has been found to be an adverse prognostic factor in AML 
(Styczynski et al., 2007). The expression of P-gp (Leith et al., 1999), MRP and LRP in AML 
was also found to correlate with advanced age (>60 years) and high white cell count (van 
delHeuvel et al., 2007). It also correlates with high risk of relapse (Daniela et al., 2007).  
There have been extensive trials conducted on AML therapy to circumvent drug resistance 
like reversion of P-gp, targeted agents against DNA replication and repair, cell cycling and 
apoptosis. 
With the extensive knowledge on P-gp efflux mechanism and its contribution to drug 
resistance in AML, quinine and cyclosporine were tested to reverse the P-gp action. 
However, these substances did not significantly improve the response rate in AML (Eric et 
al., 2003; Solary et al., 1996; Liu et al., 1998; Tallman et al., 1995). Combination of tetrandrine, 
a potent inhibitor of the MDR-1 efflux pump, with induction therapy also showed no 
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significant difference in response between P-gp positive and P-gp negative patients (Wen et 
al., 2006). Nevertheless, an early study revealed by using P-gp reversal modulators, the 
emergence of drug resistance could be prevented (Futscher et al., 1996). However, a recent 
randomized phase III trial involving 302 newly diagnosed AML patients, evaluated the 
effect of P-gp inhibitor valspodar (PSC-833) showed no difference in overall disease survival 
(Jonathan et al., 2010). Similar result was obtained in another phase III randomized trial 
involving poor risk AML patients when valspodar was added in the induction therapy 
(Peter et al., 2004) 
3. Molecular ‘signatures’ in AML 
AML is characterized by a high degree of heterogeneity with respect to chromosome 
abnormalities, gene mutations and expression of multiple genes. The heterogeneous nature 
of AML has significant clinical impact as there are marked differences in survival following 
intensive chemotherapy (explained in detail elsewhere in this book). The World Health 
Organization (WHO) classifies AML by cytogenetics, morphology, immunophenotype and 
clinical features (Swerdlow et al., 2008). Diagnostic karyotype emerges as the most 
significant prognostic factor as determined in multivariable analyses that take into account 
age, type of AML (de novo or secondary) and presenting white blood cell count (WBC), and 
accordingly provides the framework for current risk stratified treatment approaches 
(Grimwade, 2007). Nevertheless as cytogenetic and molecular genetic aberrations are not 
mutually exclusive the expression of downstream target genes that encode proteins 
involved in complex biologic networks are affected (Mrozek et al., 2009) and may alter 
predictability of standard prognostic markers. Microarray genome-wide gene-expression 
profiling (GEP) and microRNA-expression profiling assays have revealed AML signatures 
and may be readily applicable for diagnosis and outcome class prediction in AML (Mrozek 
et al., 2009). Many of the molecules involved are known mediators of signal transduction 
pathways and apoptosis. 
4. Apoptotic molecules in AML 
Apoptosis occurs principally via two separate yet interlinked signaling mechanisms: the 
extrinsic pathway, activated by proapoptotic receptor signals at the cellular surface 
(members of tumor necrosis factor, TNF, family), and the intrinsic pathway (members of 
Bcl-2 family), activated by mitochondrial signals from within the cell. These pathways 
converge through “effector” caspases, which orchestrate the apoptotic program. 
Nevertheless, each requires different initiation caspases to begin the process. The extrinsic 
pathway is activated by engagement of death receptors on the cell membrane. The death 
receptors involved in the extrinsic apoptotic pathway belong to the TNF receptor 
superfamily that include Fas (CD95 or Apo1), TNFR1 (TNF receptor 1), death receptor 3 
(DR3/Wsl-1/APO-3/TRAMP/LARD), death receptor 4 (DR4/TRAIL-R1), death receptor 5 
(DR5/TRAIL-R2) and DR6. These receptors are characterized by an intracellular death 
domain. There are also decoy receptors (i.e. DcR1 and DcR2) that contain no death domain 
or a truncated death domain and can bind ligand but cannot signal. Therefore, these decoy 
receptors function as antagonists to inhibit death ligand/death receptor-induced apoptosis. 
Binding of ligands, such as FasL, tumor necrosis factor-alpha (TNF-alpha) and TNF-related 
apoptosis-inducing ligand (TRAIL) to their respective membrane receptors Fas, TNF-R and 
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TRAIL-R induces trimerization of the receptors and recruitment of adaptor proteins such as 
the Fas-associated death domain (FADD) to the death domain. This then recruits 
procaspase-8 which then leads to the formation of the oligomeric death-induced signaling 
complex (DISC). DISC in turn promotes activation of caspase-8 and a cascade of other 
caspase enzymes that culminates with cell death (reviewed in Elrod and Sun, 2008).  
The intrinsic pathway is triggered by various extracellular and intracellular stresses, 
including growth factor deprivation, DNA damage, oncogene induction, hypoxia and 
cytotoxic drugs. Cellular signals originated by various mechanisms by these different 
stresses converge on a cellular target represented by mitochondria. Mitochondrial 
membrane permeability is controlled by pro-apoptotic (Bax, Bak, Bad, Bid, Bim, Bmf, 
NOXA, PUMA, Bok, Bcl-G, Bfk) and anti-apoptotic (Bcl-2, Bcl-L, Mcl-1, Bcl-w, A1) members 
of the Bcl-2 family, inducing or preventing heterodimerization of pro-apoptotic members. A 
series of biochemical events is induced that lead to damage of the outer mitochondrial 
membrane, with the consequent release of cytochrome c and other pro-apoptotic molecules, 
such as Smac/DIABLO, from the inner membrane into the cytosol enabling the formation of 
the apoptosome, a large molecular complex formed by cytochrome c, apoptotic protease 
activating factor 1 (APAF-1) and caspase-9, and massive activation of caspases. These 
proteins all play crucial roles for cell survival and the loss of any of these proteins causes 
major deregulation of survival of some cell types (reviewed in Ashkenazi and Herbst, 2008). 
Dysregulation of apoptosis plays an important role in the development of a variety of 
human pathologies, including cancer and particularly leukemia. The evasion of 
programmed cell death has been regarded as one of the six essential alterations in cellular 
physiology that dictate the growth of cancer cells and is a hallmark of virtually all cancers. 
Moreover, tumors that have alterations in proteins involved in cell death signaling are very 
frequently resistant to chemotherapy and are difficult to treat with chemotherapeutic agents 
that primarily act by inducing apoptosis (Testa et al., 2007). 
Fas, DR4 and DR5 are generally expressed in both normal and malignant cells. An 
examination of patients with de novo AML revealed Fas was expressed on eight of nine 
(89%) patients tested (Tourneur et al., 2004). Another study showed expression of Fas on 
62% of 29 AML patients (Min et al., 2004). Fas mutation was observed in 4/28 CML cases 
and none of the six AML cases tested (Rozenfeld-Granot et al., 2001). DR4 and DR5 
mutations detected in cancers including chronic myelogenous leukemia were very low (0–
10.6%) (Liu et al., 2005). On the other hand, DR4 and DR5 receptors were positive in 20 
(69%) and 29 (100%) patients, respectively. This study also showed, relapse-free survival 
was significantly prolonged in patients with CD95-positive AML cells compared with 
patients with CD95-negative AML cells (73% versus 38% at 3 years; p = 0.047) using 
univariate analysis (Min et al., 2004). This was however not supported by another study on 
99 AML patients where multivariate analysis showed no correlation with overall survival 
and disease free survival (Brouwer et al., 2001). 
Three ligands (TNF-α, FasL and TRAIL) of the TNF-family and their respective four 
receptors (TNF-R1, Fas, TRAIL-R1 and TRAIL-R2) are potentially important as anti-cancer 
therapeutics. The demonstration that TNF-α selectively kills tumor cells but not normal 
cells, set it up for the first molecules to be studied. Unfortunately, marked pro-inflammatory 
effects precluded its systemic administration (Buzzoni and Butler, 1996). Fas was also 
excluded as agonistic antibodies triggering Fas activation was highly hepatotoxic causing 
death in mouse models (Ogasarawa et al., 1993). In contrast, TRAIL and agonistic anti-
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TRAIL-R1/TRAIL-R2 antibodies appear to be well tolerated in vivo. TRAIL/Apo-2L 
exhibited potent anti-tumor activity and induces little cytotoxic effects in immunodeficient 
mice xenograft models implanted with several human tumor cell lines (Ashkenazi et al., 
1999). However, the in vivo half-life of the TRAIL-ligand is very short (<4 minutes) (Kelley et 
al., 2001). Agonistic TRAIL-R1 and TRAIL-R2 antibodies do not bind to TRAIL decoy 
receptors, TRAIL-R3 and TRAIL-R4, which are frequently expressed on the membrane of 
tumor cells.  
 
 
Fig. 1. Extrinsic and intrinsic pathways in apoptosis (see text for further details).  
Antisense therapies involved the use of sequences of single-stranded DNA to complement and 
bind specific coding regions on mRNA hence forming DNA–mRNA which is then degraded 
by a ribonuclease, therefore gene expression and translation are prevented. Most widely 
studied were with XIAP (X-linked inhibitor of apoptosis) and antiapoptotic proteins Bcl-2.  
Sufficient evidence exists to show that Bcl-2 was overexpressed in AML patients and 
predictive of worst outcome (Campos et al., 1993; Andreef and Konopleva, 2002). It seemed 
conceivable that Bcl-2 downregulation might lower the apoptotic threshold of leukemic cells 
and, through this mechanism, favor response to chemotherapy. Much success has been 
achieved. A phase I study using oblimersen, an antisense to Bcl-2, added during induction 
and then consolidation therapy, in elderly AML patients, induced remission in 14/27 
patients, of which seven relapsed within 12.6 months (Marcucci et al., 2005); In a multicenter 
phase II trial, 12/39 relapsed AML patients treated with oblimersen and gentuzamab (anti-
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CD33) achieved complete remission of which 10/12 survived for more than 6 months 
(Moore et al., 2004). 
XIAP binds and inhibits caspases 3, 7, and 9, mediators of the apoptotic cascade. 
Downregulation of XIAP using multiple approaches (e.g., antisense, RNAi, knock-out 
animals and cell lines, immuno-depletion) in vitro and in vivo conditions resulted in 
increased caspase activation and/or cell death. Antitumor activity was also observed with 
the use of second generation anti-sense compound, AEG35156, in xenograft models of 
cancer (Lacasse et al., 2005) Results from clinical trials however, have been variable. While 
one study on five phase 1 (12–350mg/m2 AEG35156) and eight phase 2 (350 mg/m2 
AEG35156) patients showed increased apoptotic cells and increase response (Bing et al., 
2011) another study on 27 patients randomized to receive high dose Ara-C and idarubicin 
with or without AEG35156 (650 mg) found a lower overall response rate in the group which 
received the anti-XIAP drug (Schimmer et al., 2011).  
The analysis of Mcl-1 protein expression in AML showed great heterogeneity, but the levels 
of the protein do not seem to correlate with response to standard chemotherapy (Kaufmann 
et al., 1998). Bad and Bcl-xL have been shown to be expressed in normal and leukemic 
hematopoietic precursor cells. Immature hematopoietic cells do not express Bcl-2 but do 
express Bcl-xL. CD34 positive cells express Bcl-2, Bcl-xL and Bad. Bcl-2 expression is higher 
on CD34 positive cells than on AML cells. Phosphorylated Bad was expressed in AML 
(Andreef et al., 1999).  
Potential abnormalities of the various initiator caspases in AML have been explored. Levels 
of caspase-8, caspase-2 and caspase-3 are heterogeneous in AML. AML with an immature 
phenotype (i.e., M0 and M1 AML) predominantly express caspase-8L (Mohr et al., 2005).The 
significance of caspases as prognostic indicators in AML are unclear as current reports are 
still controversial may be due to the different format of molecules examined (Svingen et al., 
2000; Estrov et al., 1998; Holleman et al., 2005). 
Expression of pro- and anti-apoptotic molecules continues to be studied in AML to correlate 
its mutated state, expression, activity or methylated state with treatment outcome (Testa et 
al., 2007). At present, the prognostic utility of measurements of pro- and antiapoptotic 
molecules for predicting clinical outcome and response to chemotherapy is uncertain.  
5. Drug modulation of signaling, differentiation and apoptotic pathways 
The study of cancer cell biology in predicting treatment outcome cannot stop at the 
presentation stage as cells continue to be modified by the microenvironment and are 
ultimately subjected to chemotherapy. While remarkable progress have been achieved in 
targeted therapies, for most tumors chemo- or radiotherapy is likely to remain in the near 
future. Both chemo- and radiotherapy are designed to kill cancer cells by damaging nuclear 
DNA. DNA damage triggers the DNA damage response (DDR) which have three critical 
goals: (i) halting cell cycle progression and division to prevent transfer of DNA damage to 
progeny cells; (ii) increasing accessibility of the damage sites to- and engagement of- the 
DNA damage repair machinery, and (iii) triggering apoptosis to exterminate cells whose 
damaged DNA cannot successfully be repaired (reviewed in Darzynkiewicz et al., 2009).  
Chemotherapeutic drugs such as cisplatin, mitomycin, methotrexate, mitoxantrone, 
adriamycin, and bleomycin induce Fas expression in human cancer cells, primarily through 
a p53-dependent mechanism (Muller et al., 1998). Adriamycin, etoposide, Ara-C, cisplatin 
and camptosar were shown to induce the expression of DR4 and DR5 or only DR5 
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expression, through either p53-dependent, or p53-independent mechanisms (Wu et al., 
1997; Guan et al., 2001; Sheikh et al., 1998). Etoposide was shown to induce DR5 expression 
in human acute leukemia cells (Wen et al., 2000). 
To complete induction of cell death, chemotherapeutic drugs have to suppress survival 
mediators in activated signaling pathways. Paclitaxel treatment of transfected MDA MB-435 
human breast carcinoma cell line was observed to downregulate phosphorylated Akt (Klos 
et al., 2003). Nevertheless, chemotherapy induction of cell death is not equal in all cells. 
Adriamycin produced differential responses in Akt phosphorylation and kinase activity in a 
panel of breast cancer cell lines. While MCF7, MDA468 and T47D cells showed a dose 
dependent increase in p-Akt levels; in contrast, SKBR3 and MDA231 cells showed a dose-
dependent decrease and no or minimal change was detected in MDA361, MDA157 and 
BT474 cells (Li et al., 2005). The diversity in response may also be predictive of a 
heterogeneity in treatment outcome. 
Other signaling molecules are activated by chemotherapeutic drugs leading to cell death. 
Ara-C induced apoptosis in HL-60 cell lines through the activation of p38 (Stadheim et al., 
2000). Adriamycin was shown to activate Jnk in a T cell leukemia cell line (Yu et al., 1999). 
Leukemia cell lines (TF-1 and K562) primed for apoptosis were also revealed to stimulate 
Jnk and p38 phosphorylation (Tucker et al., 2004) 
Certain cytokines have apoptotic activity. TNF-alpha and IFN-gamma induced the 
expression of DR5 in a number of cancer cell lines (Meng and El-Deiry, 2000). IFN-gamma 
had differential effect on induction of death receptors in colon carcinoma cell lines. While it 
raised the levels of CD95 membrane 6 – 8-fold, it had no effect on the TRAIL-receptors (DR4, 
DR5, DcR1 and DcR2) (van Geelan et al., 2003). Interferon-alpha was also reported to 
increase DR5 expression in human hepatoma (Shigeno et al., 2003). 
In contrast some cytokines exert protective effect from chemotherapeutic drug induced cell 
death, decreasing the effectiveness of cancer radiotherapy and chemotherapy. Normal 
hematopoietic cells, like other normal cell types, die by the process of apoptosis when 
deprived of viability inducing cytokines that include colony stimulating factors (CSFs) and 
various other cytokines. Induction of apoptosis by cancer chemotherapy such as vincristine, 
adriamycin, methotrexate and Ara-C was suppressed by IL (interleukin)-6, IL-3, 
granulocyte-CSF (G-CSF), granulocyte-monocyte CSF (GM-CSF) and IFN-gamma in 
myeloid leukemia cells (reviewed in Lotem and Sachs, 2002). These cytokines upregulate 
pro-survival molecules such as Bcl-2 [IL-2, IL-3, stem cell factor (SCF), IFN-gamma], Bcl-xL 
[IL-3, IL-6, IL-7, IL15, GM-CSF, IFN-gamma and erythropoietin (EPO)] and other apoptosis 
suppressing genes such as Survivin (Carter et al., 2001), X-linked inhibitor of apoptosis 
protein (XIAP) and cellular inhibitor of apoptosis 2 (cIAP2) (Digicylioglu and Lipton, 2001) 
that are caspase inhibitors and FLICE-like inhibitory protein (FLIP), that may disrupt the 
ability of cell surface molecules such as Fas to activate apoptosis (Kovalovich et al., 2001) 
Some myeloid leukemic cells are autonomous and do not require an exogenous source of 
cytokines for viability (Griffin and Lowenberg,1986), while others do. Thus, it is possible to 
suppress leukemia not only by cytotoxic agents or by induction of terminal differentiation, 
but also by decreasing the in vivo supply of apoptosis suppressing cytokines or the response 
of leukemic cells to these cytokines (reviewed in Sachs, 1996). 
A characteristic abnormality of leukemia cells is that they are blocked at an early stage of 
their development. Myeloid leukemic cells however can be induced to differentiate to non 
dividing mature granulocytes and macrophages by different cytokines, including cytokine 
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independent myeloid leukemic cells that were induced to differentiate with IL-6. Different 
myeloid leukemic clones however have different blocks and ability to undergo 
differentiation by cytokines. Our own work on in vitro cultured AML blasts exhibited 
different degrees of spontaneous apoptosis. Univariate analysis of 13 AML patients 
revealed blasts with lower levels of cell viability after 72h culture was significantly 
correlated with a longer disease free survival . Within a smaller number of samples (n=7) 
we observed blasts with lower levels of cell viability were associated with reduced levels 
CD34 and higher levels of CD16, indicating an increased level of cell differentiation (Maha 
et al., 2008). The observations may indicate an abnormal developmental program in 
leukemic cells which may be reprogrammed epigenetically by appropriate differentiation 
inducing cytokines. Constitutive expression of transcription factors such as c-myc, c-myb 
and E2F1 (Gonda and Metcalf, 1984; Blatt et al., 1992; Melamed et al., 1993) as well as 
others such as the homeobox gene Hox B8 (Hox 2.4) (Blatt et al., 1992) or GATA-1 (Tanaka 
et al., 2000), disrupted the ability of cells to undergo cytokine induced differentiation 
(reviewed in Lotem and Sachs, 2002) 
Cytokines as a differentiation treatment against leukemia however has been disappointing. 
Hematopoietic leukemia cell lines of myeloid origin such as K562, U937, HL-60, CS-1, KG-1, 
MUTZ-3, or ex vivo AML or chronic myeloid leukemia (CML) blasts were modestly 
permissive to induction of in vitro differentiation by EPO, G-CSF, GM-CSF, IL-4, IL-6, SCF, 
or synergistic combinations of several cytokines (Leung et al., 2005; Koss et al., 1996; Goliaei 
et al. 1998; Kamano et al., 1994; Kamijo et al., 1990). A niche for hematopoietic cytokines in 
differentiation therapy exists in the treatment of congenital neutropenia disorder. The 
administration of G-CSF to patients has overcome a block of myeloid differentiation leading 
to a substantial prolongation of their survival (Berliner, 2008). 
Clinically, differentiation therapy has been most successful in acute promyelocytic leukemia 
(APL) using all-trans-retinoic acid (ATRA) as the inducer. This targeted APL cells carrying 
the chromosomal translocation between chromosomes 15 and 17 [t(15;17)(q22;q21)]. 
Subsequently, APL therapy was improved with the combination regimen of ATRA with 
cytotoxic chemotherapy. Currently, complete remission rates of up to 90% to 95% are 
achievable using ATRA/ATO (arsenic trioxide) and anthracycline-based chemotherapy 
(Niu et al., 1999; Soignet et al., 2001; Raffoux et al., 2003; Ghavamzadeh et al., 2006; Mathews 
et al., 2006; Estey et al., 2006; Sanz et al., 2008). 
Another targeted treatment with tyrosine kinase inhibitor (TKI) imatinib for the treatment of 
CMLalso achieved better success. Gefinitib and erlotinib which inhibit the intracellular 
tyrosine kinase activity of epidermal growth factor receptor (EGFR), induce a differentiation 
program in myeloid leukemia cells that corresponds to neutrophil maturation (Stegmaier et 
al., 2005; Boehrer et al., 2008a; Boehrer et al., 2008b). 
These results together emphasize further not only the heterogeneity of leukemias but also 
complexity of host-cancer interaction and its influence on outcome in survival and also 
during induction of cell death. 
6. In vivo drug induced molecular profiles: Potential predictor of drug 
resistance 
The in vivo molecular changes in acute myeloid leukemia cells early after start of 
conventional genotoxic chemotherapy are incompletely understood, and it is not known if 
early molecular modulations reflect clinical response. As increasing evidence is proposing 
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tumor-host mechanisms as important for effective chemotherapy, there is an immediate 
need to investigate these issues in vivo in human cancer (Oyan et al., 2009) 
For that purpose, blasts from patients undergoing chemotherapy were collected as a 
‘natural’ and rich source to study response of these cells to the myriad of signals they were 
subjected to. Even though cells undergo cell death, as white blood cell counts may decline at 
early stages of chemotherapy, very low percentages of apoptotic cells were detected. Oyan 
et al. (2009) comparing treated (‘3+7’, idarubicin + Ara-C ) with untreated AML cells from 
seven patients, observed upregulation of 113 genes (23 of unknown function) at early time 
points (2 – 4 hours) and 108 genes at late time points (18 – 24 hours). Among the 113 genes a 
substantial number (31 genes) were related to the tumor suppressor p53 (Oyan et al., 2009). 
p53 is implicated to affect a variety of cellular processes, the most undisputed roles of p53 
are to induce growth arrest and to induce apoptosis (Bates and Vousden, 1996). p53 is the 
most commonly mutated gene in a variety of human cancers (Greenblatt et al., 1994). In 
AML however, mutations of p53 are rare, occurring in approximately 5% to 10% (Fenaux et 
al., 1992) but in these cases it correlates with worse outcome (Wattel et al., 1994). Wild-type 
p53 appears to change the balance in expression of apoptosis-inducing versus apoptosis-
suppressing genes in favor of the former and thus induce apoptosis. 
In tune with the above, a significant increase in gene expression of the apoptosis facilitators 
PUMA and Bax and a decrease in the Bcl-2 /Bax ratio as well as Bcl-2 /PUMA were 
observed for most of the AML samples. The mRNA profile of three other pro-apoptotic 
mediators Bad , Bak1 and Bim did not change significantly during the first hours, but the 
level of gene expression varied across patients. Altogether five tumor necrosis factor-related 
receptor genes were modulated 2–4 h after induction therapy (Oyan et al., 2009).  
Induction of ligand to death receptor during chemotherapy was also supported by Devemy 
et al. (2001) who observed increased TNF transcripts in treated AML cells. We also studied 
molecular changes in paired AML samples at diagnosis and during chemotherapy ( Ara-C + 
daunorubicin). We showed increased TNF-alpha was significantly higher in chemo-sensitive 
patients. Thus, expression of TNF-alpha early during chemotherapy may be a marker to 
predict good treatment outcome. In chemo-resistant cases, a higher, though not significant, 
percentage of cases expressed IL-1beta and IL-18 (Maha et al., 2009). 
We observed a significantly higher percentage of chemo-responsive AML patients with 
blasts cells increased for the expression of IL-6. This was consistent with Devemy et al (2001) 
who reported that increase of IL-6 transcripts during remission induction therapy of AML 
patients was accompanied by a fall in blood count and bone marrow cellularity. The role of 
cytokines in the induction of cell differentiation is well established. Oyan et al (2009) also 
observed several receptors expressed on monocytic/macrophage lineage cells were 
upregulated, probably related to chemotherapy induced differentiation of the leukemic 
cells. Thus, induction of cytokines expression in drug responsive AML patients may be due 
to induction of cell differentiation.  
Comparing blasts profiles before and during early chemotherapy also revealed upregulation 
of genes potentially involved in interaction between AML blasts and the host 
microenvironment. Chemokine receptors CXCR4 and CX3CR1 were upregulated in the late 
phase after start of chemotherapy indicating intention to home into a microenvironment that 
favours their growth and survival. This supports the hypothesis that the host response in 
chemotherapy is crucial for persistent remission (Oyan et al., 2009). 
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We further examined activation of signaling molecules in AML blasts. Chemotherapy 
increased the percentage of cases showing phosphorylation of the Akt molecules and 
Forkhead transcription factor (FKHR) but no significant differences were observed between 
chemo-resistant and chemo-sensitive cases. We however, observed a significantly higher 
percentage of chemo-resistant cases showing phosphorylation and inactivation of the pro-
apoptotic Bad molecule. A higher percentage of chemo-sensitive cases were phosphorylated 
for p38, and Jnk (Maha et al., 2009). In summary, we were able to show in chemo-sensitive 
cases, chemotherapy stimulated IL-6, induced apoptosis by up-regulating TNF-alpha and 
downregulated phosphorylated Bad. In reverse, in chemo-resistant cases, cells survived by 
maintaining high levels of phosphorylated Bad maybe through protective role of IL-1b and 
IL-18 cytokines (Maha et al., 2009). 
Most anticancer drugs exert their effects by the induction of apoptosis and/or interfering 
with cell cycle progression. Often these drugs give rise to specific patterns of cell death and 
cell cycle arrest that vary according to the drug used and the molecular status of the target 
cell. Simple in vitro methods may aid in this investigation. Drug cytotoxicity and sensitivity 
of individual tumor samples was demonstrated by combining cytochrome c and propidium 
iodide staining of DNA content and detected on flowcytometry. This method elucidated 
mitochondrial resistance mechanisms which may prove useful in identifying the apoptosis-
sensitive cell cycle phase for a given tumor sample/anticancer drug combination. It offers 
the opportunity to design personalized drug regimens and to identify new combined 
treatment modalities (Mohr et al., 2004).  
7. Conclusion 
The heterogeneity in AML continues to elude the best methods to characterize them. 
Genome and proteome-wide analysis has further revealed complexity in the makeup of the 
leukemic cell. The rapid advancement in targeted therapies implied the urgent need for 
alternative therapy and the readiness of the community to embrace it. Nevertheless so far, 
combinatorial medicine still holds out as the best option for successful treatment. If targeted 
therapies remain the way forward it will eventually bank deeply on the ability to identify 
molecular signatures in the individual leading to the establishment of personalized 
medicine. 
In the meantime, the mechanisms in leukemogenesis, drug resistance and relapse remain an 
area of much research. From cell biology to cytogenetics to molecular defects to signaling 
pathways, all have contributed to a better understanding of cancer biology. New knowledge 
in epigenetics and microRNA remain to be elucidated. 
Current diagnostic and prognostication are based on the assumption that the phenotype of 
the leukemic cell is static and thus definitive. There is much evidence that suggest 
otherwise. Activation of oncogenes leads to constitutive expression of signal transduction 
pathways involved in cell survival and anti-apoptotic activities. These pathways are 
multiple and made up of a myriad of molecules that are receptive to the environment. The 
host-cancer microenvironment is a dynamic microcosm of interacting signals and cascading 
molecules that constantly respond to stimuli in the surrounding to find a balance that 
maintains survival. In the course of treatment, blast cells are exposed to DNA damaging 
cytotoxic agents which trigger a gamut of other signaling mediators to exert the opposite 
effect. It would appear that a struggle ensues in which the strength of the victor determines 
whether the blast cell would maintain life or be pushed off-balance and replaced with a new 
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profile signaling cell death. This new phenotype corresponded to a sensitive response to 
chemotherapy. On the other hand, cells may strengthen on pro-survival features which 
corresponded with resistance to chemotherapy. A few reports, including ours, are lending 
support to this hypothesis. 
Unsurprisingly, chemotherapy-induce phenotype is not confined purely to either a survival 
or an apoptosis profile but a complex mix of conflicting signals to survive or die in addition 
to triggers to shut down cell proliferation, induce terminal differentiation or activate 
inflammatory responses. Thus, further elucidation of these profiles would involve 
assignment of each of the modulated molecule to its rightful pathway. 
The immaturity feature in leukemias will undoubtedly be a factor that will further 
compound the heterogeneity in results obtained. An example is the striking correlations 
found between lower Bax/Bcl-2 ratio and higher progenitor marker expression, such as 
CD34, CD117 and CD133 antigens, confirming the link between this apoptotic index and the 
maturation pathways (Del Principe et al., 2005). Attempts to induce cell death by triggering 
death receptors has so far achieved mix results with the use of TNF-alpha, Fas ligands and 
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (i.e., DR4 and DR5). 
These molecules also selectively kill cancer cells while sparing normal cells (reviewed in 
Elrod and Sun, 2008). These results indicate a preferential expression of specific death 
receptors on different tissues. 
Selection of lab methods for prognostication depends on the ability to identify lineage, 
maturation stages, genetic aberrations and activated signal transduction pathways. This feat 
may include the difficult task of combining surface markers, cytokines (secreted proteins) 
and phosphorylated proteins (unstable intracellular proteins) in the same tube on the same 
platform such as flowcytometry. Furthermore many of these proteins such as TNF-a, IL-6, 
p38 and Jnk have dual function of pro-survival and pro-apoptosis capabilities depending on 
the stimulating conditions cells are exposed to at that period of time. Precise markers will be 
required to differentiate these situations. Altogether, all of these add up to an interesting 
and exciting field of research for the immediate future. 
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